INTRODUCTION
============

Vaccines are the most efficient health care intervention for preventing morbidity and mortality and improving public health, except for water sanitation ([@B148]). The field of vaccinology originated in 1796 when Edward Jenner protected James Phipps against smallpox by inoculation with cowpox ([@B64]; [@B9]; [@B139]). However, despite dedicated efforts to develop vaccines against a range of viral, bacterial, or parasitic diseases, approximately one third of all deaths (at least 15 million people each year) and 68% of deaths in children under 5 years of age (5 million children each year) are due to infectious diseases ([@B149]). Of these, three pathogens that cause chronic infections -- the *Plasmodium* parasite, human immunodeficiency virus (HIV) and *Mycobacterium tuberculosis* (TB); known by public health officials as the "big three" -- are the major threats responsible for 10% of all deaths globally and more than half the global burden of infectious diseases. Moreover, although there is an extensive vaccine portfolio against viral and bacterial pathogens, there are no licensed vaccines for any parasitic infection of humans or for any chronic infections by complex pathogens ([@B146]; [@B89]). Indeed, there is only one therapeutic vaccine approved by the US Food and Drug Administration (FDA) or European Medicines Agency (EMA), for a metastatic hormone-refractory prostate cancer (Provenge^®^, DendreonCorp, USA) but this requires preparation of a personalized vaccine for each patient and so is expensive (∼\$US93,000) and has very poor uptake. New approaches for the development of vaccines against complex and chronic pathogens are urgently needed. Malaria is an excellent model for such approaches, being a complex pathogen which causes chronic infections and one of the "big three" public health targets.

The Malaria Vaccine Technology Road Map was published in 2006 as the result of a collective effort by the malaria vaccine community ^[1](#fn01){ref-type="fn"}^. A comprehensive update to this roadmap was released in 2013 with the strategic goal to, by 2030, license vaccines targeting *Plasmodium falciparum* and *P. vivax* with a protective efficacy of at least 75% against clinical malaria with a duration of protection of at least 2 years and booster doses to be required no more frequently than annually ^[2](#fn02){ref-type="fn"}^. In the intervening years, there has been a call for global malaria eradication, issued by Bill and Melinda Gates in October 2007 ([@B110]) and taken up the malaria community with a consensus community-based Malaria Eradication Agenda ^[3](#fn03){ref-type="fn"}^. Many experts consider that vaccines will play a key role in the eradication process ([@B60]; [@B105]) and vaccines will certainly be important to sustain and improve on levels of control achieved by other interventions such anti-malarial drugs, insecticide spraying and insecticide-impregnated bed nets. Additionally, the Global Vaccine Action Plan 2011--2020 compiled by stakeholders from the global health community including the World Health Organization (WHO), the United Nations Children's Fund (UNICEF), the National Institute of Allergy and Infectious Diseases (NIAID), and the Bill & Melinda Gates Foundation (BMGF) included as a key indicator of progress towards one of its six strategic objectives, "proof of concept for a vaccine that shows greater or equal to 75% efficacy for HIV/AIDS, tuberculosis or malaria" by 2020 ([@B147]).

However, despite intense effort for many decades by researchers throughout the world, the development of a malaria vaccine that meets the stated goals remains elusive ([@B127]). Almost all efforts have focused on the pre-erythrocytic or asexual blood stages of *P. falciparum* although recent efforts have been also directed to the sexual stage to provide 'herd immunity' rather than confer individual protection as a consequence of the malaria eradication agenda, as well as *P. vivax* ([@B124]; [@B149]). An efficacious pre-erythrocytic vaccine is considered ideal since it would halt the development of the parasite in the liver stage and thereby prevent the blood stage of the life cycle which is the stage associated with the development of clinical symptoms, as well as the transmission of the disease which occurs in the sexual stage. The most advanced malaria vaccine candidate is RTS,S, a hybrid virus-like particle containing the C-terminus of the *P. falciparum* circumsporozoite protein (CSP) fused to hepatitis B surface antigen, expressed in *Saccharomyces cerevisiae* together with hepatitis B surface antigen ([@B6]). Recently, regulatory approval for RTS,S/ASO1 targeted at infants aged 6--14 weeks and administered through the routine Expanded Program on Immunization (EPI) has been submitted to the European Medicines Agency by GlaxoSmithKline following pivotal Phase III evaluation at 11 sites in sub-Saharan Africa; if the required regulatory approvals are obtained and the Phase III safety and efficacy data are satisfactory, the WHO has indicated that a policy recommendation for RTS,S may be granted in 2015 ^[4](#fn04){ref-type="fn"}^. Although modeling estimates predict that this vaccine should have a public health impact in terms of number of "deaths averted" ([@B20]; [@B93]), the Phase III efficacy of the vaccine for its intended outcome in the target age group is very low and is not sustained ([@B42]; [@B97]). Specifically, after 18 months of follow-up, efficacy against clinical malaria was only 27% among infants aged 6--12 weeks at the first vaccination; among children aged 5--17 months at first vaccination, vaccine efficacy was 46%; moreover, these results were achieved on top of existing malaria interventions including insecticide-treated bed nets used by 86 and 78% of trial participants aged 6--12 weeks or 5--17 months, respectively ^[5](#fn05){ref-type="fn"}^. Although the RTS,S data are encouraging, this milestone has taken almost 30 years of extensive preclinical and clinical development by GSK in partnership with the US Army, supported by more than US\$200 million from the Bill & Melinda Gates Foundation in addition to more than \$350 GSK funds to date, with an additional \$260 million investment anticipated^5^ ([@B6]).

CHALLENGES FOR MALARIA VACCINE DEVELOPMENT
==========================================

The development of an effective vaccine against malaria has been hindered by the complexity of the *Plasmodium* spp. parasite as well as the host response to the parasite. Recent evidence indicates that the *Plasmodium* parasite has co-evolved with the human host for 1000s of years ([@B79]) with evolutionary co-adaptation allowing for chronic persistence of the parasite in the human host, and recurrent infections ([@B104]). The *Plasmodium* life cycle involves both invertebrate (mosquito) and vertebrate (mammalian) hosts, with multiple stages within the host (sporozoite, liver, asexual blood stage, sexual) and numerous intracellular and extracellular environments in which the parasite develops ([@B72]). Different host responses are required to target these distinct life cycle stages -- primarily antibodies against the extracellular parasite stages exposed in the peripheral circulation (sporozoites, asexual blood stage merozoites) and T cells against the intracellular stages (hepatic/liver stages) which are not accessible to circulating antibodies. In addition, the *Plasmodium* spp. parasite has a large 23 megabase genome that contains an estimated 5,300 putative proteins, many of which are expressed in different stages of the life cycle ([@B51]). Moreover, many of these protein may exhibit allelic polymorphism (more than one allele existing for certain regions of a protein, e.g., MSP1 or AMA1), antigenic polymorphism (point mutations at the nucleotide level, e.g., CSP) often localized to B cell or T cell epitopes, or antigenic variation (multi-copy variant surfaces antigens, e.g., var genes, rifins; [@B53]; [@B133]; [@B67]; [@B7]). A vaccine must be effective against all antigenic or allelic variants responses, to ensure efficacy against all variant circulating strains in the field ([@B89]). In addition to this selection by the parasite of mutations that avoid the host protective immune response and confer susceptibility to the disease, there is selection by humans of mutations that confer resistance. Indeed, malaria is considered to have had the greatest impact of all pathogens in shaping the human genome with evidence that a number of genetic polymorphisms within the human genome, including α*-thalassemia* and hemoglobinopathies such as the sickle-cell trait, have arisen due to evolutionary pressure exerted by the *Plasmodium* parasite ([@B82]; [@B135]). The high mortality rate associated with malaria would be predicted to exert a powerful selective pressure on the human genome by positively selecting any genetic mutation that confers protection against death to allow the *Plasmodium* parasite to persist in the host and be transmitted ([@B104]; [@B82]). Other sophisticated immune evasion strategies at the host-parasite interface include the ability of the parasite to modulate the host immune response, reviewed extensively elsewhere ([@B72]; [@B25]; [@B104]). These complex host--parasite interactions at the genetic and immunological levels pose significant challenges for vaccine development.

FEASIBILITY OF VACCINATION AGAINST MALARIA
==========================================

In spite of these challenges, there is growing evidence supporting the feasibility of developing an effective malaria vaccine. Field studies have demonstrated a decreasing incidence and density of infection with age and exposure to natural infection, and reduced frequency and severity of clinical illness, indicative of the acquisition of anti-disease immunity ([@B5]; [@B34]). Also, passive transfer of polyclonal sera or purified immunoglobulin from individuals with lifelong exposure to *P. falciparum* resulted in a significant reduction in blood-stage parasitemia and recovery from clinical symptoms ([@B28]; [@B117]). Those studies implicate antibodies directed against blood stage antigens as the key immune effectors in naturally acquired immunity. This protection is anti-disease immunity but not anti-parasite immunity since most individuals with long-term exposure in malaria endemic areas who have developed effective clinical immunity will nonetheless continue to experience low-density, asymptomatic infections ([@B96]). Longitudinal studies in malaria-endemic populations suggest that immune responses to the pre-erythrocytic stages probably have limited involvement in this anti-disease immunity and that immunity to the pre-erythrocytic stage is not naturally acquired ([@B101]; [@B136]). Nonetheless, epidemiological studies suggest that exposure to low numbers of sporozoites, although not sterilizing, can reduce the parasite load in the liver and lower blood stage parasitemia, since the intensity of exposure to biting infectious mosquitoes (entomological inoculation rate) has been significantly associated with the incidence and density (but not prevalence) of *P. falciparum* parasitemia in children ([@B34]).

More convincing evidence for the feasibility of vaccination against malaria exists from studies focused on the experimental induction of protective immunity, which have established that sterile infection-blocking protective immunity directed against the pre-erythrocytic stage can be achieved in mice and humans. Considered for many years the "gold standard" for malaria vaccine development, sterile protection can be induced in mice, non-human primates and humans by exposure to the bites of radiation-attenuated *P. yoelii, P. berghei, P. knowlesi*, or *P. falciparum* infected mosquitoes, or by intravenous immunization with isolated irradiated sporozoites, provided that the dose of radiation is sufficient to attenuate the parasite such that it can invade the hepatocyte but not develop into the blood-stage ([@B94]; [@B58]; [@B63]; [@B143]). The parasite is arrested in early liver stage development, with each invading sporozoite giving rise to only a single hepatic parasite. Murine and non-human primate studies establish that the protective immunity induced by immunization with radiation attenuated sporozoites (RAS) is directed against the liver stage parasite and mediated primarily by CD8^+^ T cells and IFN-γ ([@B122]; [@B36]; [@B138]; [@B143]). Recent studies have shown that protection in humans can be induced in a dose-dependent manner by intravenous but not intradermal immunization with radiation-attenuated, aseptic, purified, cryopreserved *P. falciparum* sporozoites ([@B44]; [@B125]); five intravenous doses of 135,000 *Pf*SPZ (675,000 sporozoites in total) were required to achieve sterile immunity in 6/6 volunteers. CD8^+^ IFN-γ-producing T cells in the liver were implicated as the primary immune effector based on non-human primate studies showing that high frequencies of CD8^+^ T cells could be induced by intravenous but not intradermal routes of immunization, and mouse studies showing that these cells could protect ([@B44]). These data are consistent with an earlier proposal ([@B72]) that sporozoites injected intravenously can enter the liver within seconds and be processed and presented by liver-resident antigen-presenting cells for induction of host immunity, whereas sporozoites inoculated intradermally via mosquito bite may take minutes to hours to enter the liver; or might may be taken up by a different type of antigen presenting cell such as the skin-derived CD103^+^ dendritic cells ([@B11]).

Sterile immunity against *Plasmodium* sporozoite challenge can be also induced in mice by homologous immunization with infectious (live) wild type sporozoites while receiving a prophylactic regimen of chloroquine ([@B10]; [@B98]; [@B13]) or primaquine ([@B109]). This immunity is directed against the liver stage and mediated by CD4^+^ and CD8^+^ T cells, but not antibodies ([@B13]; [@B111]). More recently, this observation has been translated to humans with the demonstration that human subjects exposed three times to the bites of 10-15 *P. falciparum* infected mosquitoes under the cover of chemoprophylaxis (ChemoProphylaxis and Sporozoites, CPS-immunization; also known as infection--treatment--vaccination, ITV) were sterilely protected against subsequent challenge with *P. falciparum* sporozoites, but not *P. falciparum-*infected erythrocytes ([@B111]; [@B15], [@B16]). This protection was sustained for up to 2 years ([@B112]) and was dose dependent: complete protection was obtained in 4/5, 8/9, and 5/10 volunteers immunized three times with bites from 15, 10, or 5 *P. falciparum*-infected mosquitoes, respectively, and CPS immunization is thus estimated to be about 20 times more efficient than RAS immunization ([@B16]). Since chloroquine kills asexual blood stage parasites but not sporozoites or liver stage parasites, in the CPS-model parasite infection is aborted in the early phase of blood-stage infection allowing full liver-stage development of the parasite. Consequently, CPS immunization exposes the host to parasite antigens expressed in early and late liver stages as well as early blood stages ([@B15]). However, the protective immunity appears to be directed primarily against the liver-stage of the parasite since CPS-immunized volunteers showed no evidence of protection against blood-stage challenge *in vivo* and IgG from CPS-immunized volunteers did not inhibit asexual blood-stage growth *in vitro* ([@B15]). Moreover, this protection appears to be mediated by T cells since protected subjects had significantly higher proportions of CD4^+^ T cells expressing the degranulation marker CD107a and CD8^+^ T cells producing granzyme B after *in vitro* restimulation with *P. falciparum*-infected red blood cells ([@B16]), and antibodies to nine antigens representing different stages of the *P. falciparum* life cycle did not predict protection ([@B91]) even though CPS-immunization induced functional antibodies against *P. falciparum* sporozoites which could inhibit sporozoite traversal through hepatocytes and liver-stage infection ([@B12]). The antigenic targets of the CPS-induced T cell mediated are not yet known but this is under investigation.

In a variation on the CPS approach, the induction of robust protective immunity by prophylactic administration of antibiotic drugs which specifically inhibit apicoplast biogenesis during exposure to intravenously or mosquito bite transmitted sporozoites was reported in the *P. berghei* murine model ([@B50]). This approach was conceived to overcome limitations of ITV associated with drug resistance parasite populations. The correct choice of antibiotic in this model allows for continued liver-stage maturation and exponential expansion of attenuated liver-stage merozoites from a single sporozoite and subsequent release into the host peripheral circulation of merosomes (detached vesicles containing liver stage merozoites) which are incapable of infecting red blood cells, thereby halting the parasite life cycle prior to the asexual blood stage. This immunity appears to be targeted at the liver stage and mediated primarily by CD8^+^ T cells and IFN-γ. This strategy is distinct from the RAS model where each sporozoite gives rise to only a single attenuated liver-stage parasite, and the primaquine chemoprophylaxis model where liver-stage development is aborted before the onset of nuclear divisions ([@B109]), and the chloroquine chemoprophylaxis model which targets the early blood-stage ([@B13]; [@B111]).

Another area of active investigation is genetically attenuated parasites (GAP) generated via targeted disruption of genes essential for liver-stage or blood stage development ([@B90]). These have been comprehensively reviewed elsewhere ([@B22]; [@B83]; [@B92]) and include GAPs that arrest development early (Δp52/Δp36, ΔSAP1, ΔSLARP) or later (ΔUIS3/UIS4, ΔE1a, ΔE3, ΔFABI, ΔFABB/F, ΔFABZ, and ΔPKG) during liver stage development. In a first-in-human safety and immunogenicity clinical trial, 5/6 volunteers administered GAP sporozoites deleted of two *P. falciparum* pre-erythrocytic stage-expressed genes (P52 and P36) via mosquito bite did not develop blood stage parasitemia ([@B130]). However, the development of peripheral parasitemia in one volunteer showed that this double knockout GAP was incompletely attenuated. Although no breakthrough blood infections were observed in a study evaluating the *P. yoelii* Δp52/Δp36 GAP ([@B71]), others observed developing *P. berghei* or *P. falciparum* liver stages *in vitro* culture with the respective Δp52/Δp36 GAPs and breakthrough blood infections in *P. berghei* Δp52/Δp36 GAP immunized mice, showing that the Δp52/Δp36 GAP was not adequately attenuated ([@B4]). A minimal set of screening criteria has been proposed to assess the adequacy of genetically attenuation before advancing candidate GAPs into further clinical development ([@B4]). Most recently, a triple gene deleted GAP (*Pf* Δp52/Δp36/Δsap1) had been shown to be completely attenuated in a humanized mouse model ([@B86]).

Vaccination with chemically attenuated parasites is also being pursued. In the original studies in mice, chemical attenuation of *P. yoelii* or *P. berghei* sporozoites with the DNA sequence-specific alkylating agent centanamycin conferred sterile immunity *in vivo* following one to three intravenous doses (50/20/20K) of centanamycin-treated *P. yoelii* or *P. berghei* sporozoites ([@B107],[@B108]). The level of protection, parasite-specific antibodies, and IFN-γ-producing CD8^+^ T cell responses induced by chemically attenuated sporozoites (CAS) were similar to those induced by RAS. In the blood stage, Good et al., (2013) have recently reported that a single immunizing dose of 10^6^ *P. chabaudi* parasitized red blood cells chemically attenuated with centanamycin could protect against challenge with 10^5^ homologous or heterologous (*P. vinckei* and *P. yoelii*) parasites in a CD4^+^ T cell dependent manner ([@B54]). Chemically attenuated *P. falciparum* parasitized red blood cells are currently being evaluated in the clinic (Good, personal communication).

Another whole organism based strategy directed at the blood stage of the parasite life cycle was designed to induce T helper 1 (Th1) cell mediated immunity in the absence of antibodies by immunizing with subpatent ultra-low dose parasitized erythrocytes followed by drug treatment ([@B106]). This built on observations that parasites in high density could cause apoptosis of parasite-specific T cells ([@B62]; [@B150]). [@B54] showed that malaria-naive humans deliberately infected four times with approximately 30 viable parasitized red blood cells followed by drug treatment developed robust T cell responses in the absence of antibody which prevented parasite growth in three of four individuals and delayed the onset of parasite growth which remained subpatent in the fourth individual ([@B106]). Efficacy against a higher dose challenge post-immunization was not assessed, and the contribution of residual drug to this protection could not be excluded. This ultra-low dose immunization approach has not yet been repeated in humans or mice. However a subsequent study in the *P. chabaudi* model demonstrated that three intravenous infections with a relatively high dose of 100,000 *P. chabaudi* infected erythrocytes followed by drug cure after 48 h and before microscopic patency could protect mice against a 10-fold higher (10^6^) parasite challenge; mice had robust cell-mediated immune responses and antibodies to merozoite antigens but variant-specific antibodies were not detectable ([@B43]).

These proof-of-concept studies with whole organism based vaccines show that experimental induction of sustained protective immunity to *Plasmodium* spp. parasites is possible.

MALARIA VACCINE STRATEGIES
==========================

Evidence that immunity can be induced experimentally or acquired naturally with age and/or exposure suggests two fundamental approaches to vaccine development ([@B52]):

1.  \(1\) Induce robust immune responses against a selected panel of antigens recognized as immunodominant in the context of natural infection.

2.  \(2\) Induce a broad immune response against a large number of parasite antigens not necessarily recognized as immunodominant in the context of natural infection in order to mimic the immunity induced by the whole parasite.

Until recently, almost all malaria vaccine efforts have been directed at the former approach. Most of these subunit efforts have targeted only a very small number of target antigens, focusing almost exclusively on CSP for the pre-erythrocytic stage and MSP1 and AMA1 for the blood stage ([@B124]; [@B149]) and investigating a variety of vaccine delivery systems. A major emphasis has been on purified recombinant proteins formulated with adjuvant, but viral vectored approaches have become of increasing interest, particularly for the pre-erythrocytic stage where induction of parasite-specific T cell responses is desirable. These have been reviewed extensively elsewhere ([@B21]; [@B30]; [@B3]; [@B124]; [@B17]). However, despite extensive efforts throughout the world spanning many decades and in contrast to the immunity induced by experimental immunization with variations of whole organism based vaccines, candidate subunit vaccines against malaria have been poorly efficacious ([@B124]; [@B149]). Indeed, it is not surprising that a vaccine based on a single antigen is unlikely to confer solid protection against a complex multi-lifecycle stage parasite expressing thousands of proteins that has co-evolved with the human host for millennia.

This marked lack of success in single-antigen subunit based vaccines, combined with the recognition that an effective malaria vaccine will likely need to be a multi-stage multi-immune response vaccine ([@B35]) given the challenges described above, has caused a resurgence of interest in whole organism vaccine approaches, intended to reproduce the protective immunity induced by exposure to the parasite in experimental challenge models or naturally in the field. However, a number of challenges are associated with whole organism based vaccine strategies ([@B85]; [@B6]; [@B3]). Specific concerns with GAPs include potentially inadequate attenuation, as already demonstrated with the *Pf* Δ52/Δp36 GAP in the only human trial to date ([@B130]), and reversion to virulence of a parasite that has co-evolved with the human host for millennia if it is genetically modified in only one or a few regions of its genome. Other concerns include logistical challenges associated with manual dissection of sporozoites, route of administration, loss of viability upon cryopreservation, and cold-chain requirements. Additionally, antigenic variability of the parasite means that robust cross-protection from a single strain product is essential. Thus, although promising results have been obtained in preclinical models, it remains to be seen whether the many technical, logistical, and regulatory hurdles associated with large-scale production and field deployment of live-attenuated parasites can be overcome.

Even if these technical, logistical, and regulatory challenges can be overcome, a key question is whether whole parasite approaches will induce optimal immunity. Those approaches are essentially similar to the classical "identify, isolate, and inject" approach pioneered in the late 17th century by Edward Jenner, which has proved successful with a wide range of bacterial and viral pathogens, but not yet any parasitic pathogens or any chronic diseases (reviewed in [@B33]). This could be attributed to the complexity of parasites as compared to viruses and bacteria, with larger genomes and multiple intracellular and extracellular life cycle stages. Additionally, it is now well established that microbial pathogens have evolved complex and efficient ways of counteracting and evading innate and adaptive immune mechanisms of the host ([@B152]). Thus, logically, robust immunity against such pathogens would not be induced by strategies using the whole pathogen intended to mimic experimentally that immunity induced by natural exposure. Rather, effective vaccination would require that we do better than nature, by inducing responses that are quantitatively and/or qualitatively different immune response to that induced by natural infection.

Inherent in this approach is the cumulative effect of multiple potentially low level immune responses directed against a number of antigens which may or may not be dominant parasite antigens, which together exceed a response threshold sufficient to protect. We proposed this "threshold of immune response concept" over 15 years ago ([@B35]). Specifically, we proposed that the intensity of an immune response will be determined by the sum of a number of signals received by a T cell (or B cell) with the appropriate receptor, and that although a single antigen (with one or more target epitopes) could be sufficient to generate a protective immune response if it is appropriately presented to the immune system, a wide repertoire of specificities at the epitope level (more antigens) should increase the probability of collectively inducing a protective host immune response. Experimental evidence that responses to a given antigen following protective immunization in mice with RAS are not as high as antigen-specific responses induced by vaccination with antigen-specific peptides, recombinant protein or live vectors which nonetheless fail to protect validates this concept. In an elegant series of studies in the *P. berghei* model, Harty and colleagues were able to define a threshold frequency of CD8^+^ T cells that predicted long-term sterile immunity against sporozoite challenge, and showed that an extremely high frequency of CD8^+^ T cells (exceeding 8% of all circulating CD8^+^ T cells in BALB/c mice and 19% in outbred mice) was required for both a single-antigen subunit vaccination ([@B121]) and RAS immunization ([@B120]); this level greatly exceeding the number of memory CD8^+^ T cells required for resistance to other pathogens.

A similar requirement for a protective threshold of antibody production for parasite clearance following lethal challenge has been demonstrated in a *P. chabaudi* model using MSP1-specific transgenic CD4^+^ T cells in immunodeficient mice, where levels of MSP1-specific antibody and the speed of their production correlated with the time of resolution of infection ([@B131]). In humans, in the field, a broad repertoire of antibody responses to multiple antigens has been associated with protection from clinical malaria ([@B99]; [@B29]).

These data suggest that to induce optimal protection against malaria, vaccination with the whole parasite is not required, and would likely be suboptimal. Rather, vaccination with only key components of the parasite that have been rationally selected in the context of relevant biological function would be preferable.

NOT ALL ANTIGENS ARE EQUAL
==========================

It is now generally recognized that not all antigens, or epitopes within a given antigen, are equal in the context of host immunity. The phenomenon whereby immune responses are mounted against only one or a few of the entire repertoire of peptide epitopes expressed on a given antigen, or antigens expressed by a given pathogen, is termed immunodominance ([@B126]; [@B2]). In theory, any of the proteins expressed by the parasite genome may be a target of protective immune responses. However, many proteins expressed by the parasite genome do not elicit immune responses, and for many if not most of the subset which do elicit immune responses, the response is not protective. Also in theory, a robust and effective immune response directed against an accessible dominant target would be highly successful in eliminating the pathogen from the host. However, as noted above, in many cases immune evasion strategies have evolved to allow the pathogen to escape the protective host response. Factors that could influence immunodominance, and their importance in protection, have not been investigated in the context of a complex pathogen, although some hypotheses exist ([@B33]).

Although immunization with whole organisms preferentially induces responses against immunodominant epitopes, responses to subdominant T cell epitopes can contribute to controlling infection ([@B49]; [@B68]; [@B115]). Also, the ability to focus the immune response away from dominant antigens or epitopes and towards subdominant antigens or epitopes could be of value in chronic diseases where T cells directed against the immunodominant antigens or epitopes might be anergic but T cells specific for non-dominant epitopes might be reactive. Translating this to infectious diseases where the development of effective vaccines based on immunodominant antigens has thus far not been successful ([@B52]), one could speculate that the critical targets of protective immunity may be those that are not dominant in the context of the whole organism.

In support of this, although the CSP is the dominant sporozoite surface protein and represents a target of immune responses induced by immunization with radiation attenuated *Plasmodium* sporozoites, those responses are much weaker than responses induced by CSP-based subunit vaccines, and responses are also directed against other non-CSP antigens ([@B37], [@B36], [@B40]; [@B70]; [@B55]; [@B137]). Notably, sterile CD8^+^ T-cell mediated immunity to sporozoite challenge could be induced by immunization with RAS in JHT transgenic mice that were tolerant to CSP, so this protection was directed against non-CSP antigens ([@B70]). Sterile protection could be also induced by RAS or CPS immunization with transgenic *P. berghei* parasites in which the endogenous CSP was replaced by that of *P. falciparum* or *P. yoelii,* respectively, despite the absence of immune responses specific to the CSP expressed by the parasite used for challenge ([@B55]; [@B84]). Also, human volunteers protected by immunization with RAS did mount CD8^+^ and CD4^+^ T cell and antibody responses to CSP but those responses were similar to, or lower than, those in immunized volunteers who were not protected against sporozoite challenge indicating that the RAS-induced protective immune responses are directed predominantly against non-CSP antigens ([@B37], [@B36], [@B40]; [@B137]). Recently, using protein microarrays, we have identified a signature of 19 mostly uncharacterized antigens which is strongly associated with RAS-induced protective immunity; reactivity to any individual antigen did not correlate with protection ([@B137]).

Accumulating experimental data in preclinical and clinical studies of malaria thus indicate that in fact not all antigens are equal, that antigen selection is important, and that it is the cumulative response to a number of key antigens that is important, rather than a dominant response to a single antigen.

GENOME-BASED VACCINE DESIGN
===========================

The identification within the hierarchy of antigens (or epitopes) expressed by the pathogen that are targets of protective immune responses and that will stimulate effective immunity against that pathogen is a key component of rational vaccine design ([@B116]). Cutting-edge technologies and screening strategies to mine genomic sequence information for state-of-the-art rational vaccine design, as well as genome-based rational vaccine design strategies, and recently reviewed elsewhere ([@B33]; [@B123]). The challenge, then, is how to select the key targets since there is no algorithm that can be applied to identify the important antigens and epitopes. Advances in the genomic era offer great potential, particularly when the genome of the target pathogen is large, and large-scale genomic, proteomic and transcriptomic datasets provide valuable resources to mine for antigen discovery.

In the case of malaria, the recent availability of large-scale genomic (**Table [1](#T1){ref-type="table"}**), proteomic (**Table [2](#T2){ref-type="table"}**), transcriptomic (**Table [3](#T3){ref-type="table"}**) and comparative data from *P. falciparum* and other *Plasmodium* species provides an unprecedented opportunity to identify key targets antigens of protective immunity amongst the large repertoire of antigens expressed by the whole parasite. Since 2002, the genomes of seven *Plasmodium* parasites have been published, including that for the two major human parasites (*P. falciparum, P. vivax*) ([@B51]; [@B23]; [@B102]); two non-human primate parasites (*P. knowlesi*, *P. cynomolgi*; [@B102]; [@B132]), and three murine parasites (*P. yoelii* 17XNL, *P. berghei, P. chabaudi*; [@B24]; [@B61]). Draft complete genomes are also available for the avian malaria parasite *P. gallinaceum*, non-human primate parasite *P. reichenowi* Denni, the lethal murine parasite *P. yoelii YM,* and three different strains of *P. falciparum* (HB3,Dd2 and IT; **Table [1](#T1){ref-type="table"}**). Partial genome sequence is also accessible for 21 isolates of *P. falciparum* and four isolates of *P. vivax* from geographically distinct areas of the world, as well as low coverage draft genomes for the other two parasites infecting humans, *P. malaria* and *P. ovale*. With the advent of next-generation sequencing technology, the sequencing of genomes for an additional 105 *Plasmodium* species/strains/isolates have been proposed by the malaria community ^[6](#fn06){ref-type="fn"}^. These parasites include 50 *P. falciparum* field isolates collected from patients in East Africa, America, and Asia; 24 *P. falciparum* parasites representing both contemporary or historical parasite strains, including strains used in drug and vaccine trials; 16 *P. vivax* isolates from Africa, America, and Asia; four non-human primate parasites (*P. reichenowi, P. cynomolgi*, *P. inui*, *P. coatneyi*, *P. fragile*); and complete sequence and closure of three murine parasites (*P. chabaudi*, *P. yoelii*, and *P. berghei* and two avian and reptile parasites (*P. relictum* and *P. mexicanum*). For some of these parasites, a first partial assembly is already available (**Table [1](#T1){ref-type="table"}**).

###### 

*Plasmodium* genomic datasets.

  Genome               Strain                                  Host                Submitter                      Status                                                                                                                                                                                                                                                             Reference
  -------------------- --------------------------------------- ------------------- ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------
  *P. falciparum*      *3D7*                                   Human               Genome Sequencing Consortium   High quality genome produced in 2002. Updated and reassembled version available on GeneDB (September 2011)                                                                                                                                                         [@B51]; GeneDB; PlasmoDB; Parasite Genomics Group (WTSI)
  *P. falciparum*      *IT*                                    Human               WTSI\*                         Draft genome produced using Sanger sequencing and Illumina sequence-by-synthesis. Annotation version available on GeneDB (March 2013)                                                                                                                              GeneDB; PlasmoDB, Parasite Genomics Group (WTSI)
  *P. falciparum*      *HB3, Dd2*                              Human               Broad Institute                Draft genomes available on NCBI^\$^ (September 2009)                                                                                                                                                                                                               NCBI
  *P. falciparum*      *20 strains*                            Human               Broad Institute                First-pass partial assemblies available on NCBI for *7G8, CAMP/Malaysia, Vietnam Oak-Knoll (FVO) D10, D6, FCH/4, IGH-CR14, K1, MaliPS096_E11, NF135/5.C10, NF54, Palo Alto/Uganda, RAJ116, RO-33, Santa Lucia, Senegal_V34.04,Tanzania, UGT5.1, VS/1, Brasil I.*   NCBI
  *P. vivax*           *Sal-1*                                 Human               TIGR                           Published in 2008. Updated and reassembled version (10x coverage) available on GeneDB (May 2013)                                                                                                                                                                   [@B23]; GeneDB; PlasmoDB; Parasite Genomics Group (WTSI)
  *P. vivax*           *India VII, Mauritiana, North Korean*   Human               Broad Institute                First-pass partial assembly available on NCBI (July 2012)                                                                                                                                                                                                          NCBI
  *P. malariae*                                                Human               WTSI                           Partial draft genome                                                                                                                                                                                                                                               Parasite Genomics Group (WTSI)
  *P. ovale*                                                   Human               WTSI                           Low-coverage draft produced using Sanger sequencing, from multiple sources of *P. ovale* DNA (Nigeria I/CDC strain and LSHTM)                                                                                                                                      Parasite Genomics Group (WTSI)
  *P. knowlesi*        *H*                                     Primate and Human   WTSI                           Published in 2008. Updated and reassembled version (8× coverage) available on GeneDB (March 2014)                                                                                                                                                                  [@B102]; GeneDB; PlasmoDB; Parasite Genomics Group (WTSI)
  *P. cynomolgi*       *B*                                     Primate             Osaka University               Draft genome obtained using Illumina Sequence-by-synthesis technology. Updated contig sequence and annotation available on PlasmoDB (September 2013)                                                                                                               [@B132]; PlasmoDB, Parasite Genomics Group (WTSI)
  *P. reichenowi*      *CDC Dennis*                            Primate             WTSI                           First-pass partial assembly produced using Sanger sequencing available on NCBI (May 2014)                                                                                                                                                                          Parasite Genomics Group (WTSI).
  *P. inui*            *San-Antonio1*                          Primate             Broad Institute                First-pass partial assembly available on NCBI (January 2014)                                                                                                                                                                                                       NCBI
  *P. coatneyi*        *Hackeri*                               Primate             NHGRI                          First-pass partial assembly available on NCBI (July 2014).                                                                                                                                                                                                         NCBI
  *P. gaboni*          *Pgk*                                   Chimpanzee          TIGR\*\*                       First-pass partial assembly available on NCBI (February 2014)                                                                                                                                                                                                      NCBI
  *P. gallinaceum*     *8A*                                    Avian               WTSI                           Low-coverage draft genome produced by Sanger sequencing. Updated high quality draft genome is being produced using Illumina Sequence-by-synthesis.                                                                                                                 Parasite Genomics Group (WTSI)
  *P. yoelii yoelii*   *17X and 17XNL*                         Murine              WTSI                           Low-coverage draft genome of 17XNL published in 2002. Updated and reassembled version of 17X available on GeneDB (May 2013)                                                                                                                                        [@B24]; [@B61]; GeneDB; PlasmoDB; Parasite Genomics Group (WTSI)
  *P. yoelii yoelii*   *YM*                                    Murine              WTSI                           First-pass partial assembly available on GeneDB (January 2012)                                                                                                                                                                                                     GeneDB; Parasite Genomics Group (WTSI)
  *P. chabaudi*        *chabaudi*                              Murine              WTSI                           Low-coverage draft genome published in 2005. Additional sequencing completed using Illumina Sequence-by-synthesis technology and available on GeneDB (March 2013)                                                                                                  [@B61]; GeneDB; PlasmoDB. Parasite Genomics Group (WTSI)
  *P. berghei*         *Anka*                                  Murine              WTSI                           Low-coverage draft genome published in 2005. Additional sequencing completed using Illumina Sequence-by-synthesis technology and available on GeneDB (March 2013)                                                                                                  [@B61]; GeneDB; PlasmoDB; Parasite Genomics Group (WTSI)
  *P. vinckei*         *Petteri, Vinkei*                       Murine              Broad Institute                First-pass partial assembly available on NCBI (2014)                                                                                                                                                                                                               NCBI

\*WTSI, Wellcome Trust Sanger Institute; \*\*TIGR, The Institute for Genomic Research;

\$

NCBI, National Center for Biotechnology Information

###### 

*Plasmodium* proteomic datasets.

  Species/Strain                            Parasite material                                                                            Method                            Description                                                                                                                                                                                     Reference
  ----------------------------------------- -------------------------------------------------------------------------------------------- --------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  *P. falciparum 3D7*                       Infected erythrocytes and gametocytes                                                        MudPIT\*                          *P. falciparum* asexual blood stage and sexual stage proteomes. 2,415 parasite proteins identified.                                                                                             [@B46]
  *P. falciparum* NF54                      Trophozoites, schizonts, gametocytes, and gamete                                             LC-MS/MS\*\*                      *P. falciparum* asexual blood stage and sexual stage proteomes. 1,289 proteins detected: 714 in asexual blood stages, 931 in gametocytes and 645 in gametes.                                    [@B73]
  *P. falciparum* 3D7                       Infected erythrocytes                                                                        MudPIT                            *P. falciparum* parasite infected erythrocyte surface proteome. 423 proteins identified.                                                                                                        [@B45]
  *P. falciparum 3D7*                       Infected erythrocytes                                                                        MudPIT                            *P. falciparum* infected erythrocyte proteome. 802 proteins identified in the nuclear proteome.                                                                                                 [@B95]
  *P. falciparum 3D7 and P. vivax Sal-1*    Infected erythrocytes                                                                        LC-MS/MS                          Proteomic analyses of clinical isolates of early stages of *P. falciparum* and *P. vivax*. 100 proteins identified.                                                                             [@B1]
  *P. falciparum 3D7, F12*                  Trophozoites, gametocytes                                                                    LC-MS/MS                          Quantitative comparative proteomics analysis of trophozoites and early gametocyte stages of *P. falciparum*. 1090 new proteins identified.                                                      [@B129]
  *P. vivax Sal-1*                          Infected erythrocytes                                                                        MS/MS^†^                          Elucidation of the *P. vivax s*chizont proteome from clinical sample. 316 proteins identified.                                                                                                  [@B113]
  *P. falciparum 3D7 and P. berghei ANKA*   Midgut and salivary glands Sporozoites                                                       nLC-MS/MS                         Proteomic comparison of sporozoites from oocysts and salivary glands. 127 proteins identified in oocysts, 450 in oocyst-derived sporozoites, and 477 in salivary gland sporozoites.             [@B74]
  *P. falciparum 3D7 and P. yoelii 17XNL*   Salivary gland sporozoites                                                                   LTQ Orbitrap Velos§, nLC-MS/MSi   Putative surface proteomes of *P. falciparum* and *P. yoelii* salivary gland sporozoites. 1991 *P. falciparum* sporozoite proteins and 1876 *P. yoelii* sporozoite proteins identified.         [@B78]
  *P. berghei ANKA*                         Mixed asexual blood stages, gametocytes, ookinetes, oocysts and salivary gland sporozoites   MudPIT                            *P. berghei* oocysts and sporozoite proteomes. 1836 proteins identified: 1139 in blood stage, 1091 in ookinetes, 733 in gametocytes, 277 in oocysts and 134 in salivary gland sporozoites.      [@B61]
  *P. berghei ANKA*                         Gametocytes                                                                                  LC-MS/MS                          Comparative proteomic analysis of male vs female gametocytes. 353 proteins in mixed-gametocyte proteome identified, 305 proteins in male gametocytes, and 170 proteins in female gametocytes.   [@B66]
  *P. yoelii 17X*                           Infected hepatocytes                                                                         LC-MS/MS                          *P. yoelii* liver stage proteome. 712 proteins identified.                                                                                                                                      [@B134]

\*MudPIT, Multidimensional protein identification technology;

∗∗

LC-MS/MS, liquid chromatography tandem mass spectrometry; nLC-MS/M S, nano flow liquid chromatography mass spectrometry;

†

MS/MS, tandem mass spectrometry; §LTQ Orbitrap Velos, TQ Orbitrap Velos mass analyzer coupled to nano-liquid chromatography

.

###### 

*Plasmodium* transcriptomics datasets.

  Species/Strain                                                                           Parasite material                                                                                                                                                                         Method             Description                                                                                                                                                                                                                                                                                                                                                                                       Reference
  ---------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------
  *P. falciparum 3D7*                                                                      Nine different life cycle stages: mosquito salivary gland sporozoites, seven asexual erythrocytic stage time ponts, and sexual stage gametocytes                                          Microarray         Gene expression profiles of human and mosquito stages of *P. falciparum* life cycle. 43% of expressed genes were cell-cycle regulated; 1489 genes regulated in erythrocytic stages, and 746 genes differentially regulated in sporozoites and gametocytes.                                                                                                                                        [@B76]
  *P. falciparum 3D7*                                                                      Trophozoites and schizonts                                                                                                                                                                Microarray         Gene-expression profile of the intraerythrocytic trophozoite and schizont stages. Revealed extensive transcriptional regulation of genes specialized for processes specific to trophozoites or schizonts.                                                                                                                                                                                         [@B18]
  *P. falciparum 3D7*                                                                      Gametocytes stages I--V                                                                                                                                                                   Microarray         Transcriptomic analysis of high-purity stage I-V *P. falciparum* gametocytes. Identified a sexual development cluster of 246 genes exhibiting highly correlated, gametocyte-specific expression patterns.                                                                                                                                                                                         [@B151]
  *P. falciparum 3D7, Dd2, HB3*                                                            Asexual erythrocytic stages                                                                                                                                                               Microarray         Transcriptome of asexual intraerythrocytic developmental cycle (3D7, 6287; Dd2, 5294; HB3, 6415 genes). 60% of genome identified as transcriptionally active during erythrocytic stage. Transcripts profiles were well conserved amongst strains, except for surface antigens.                                                                                                                    [@B18] [@B80]
  *P. falciparum:* 21 lines, from four subclonal groups (3D7A/3D7B, 7G8, D10, HB3A/HB3B)   Asexual erythrocytic stage at seven time points post-infection (10, 20, 30, 34, 37, 40, or 43 h)                                                                                          Microarray         Asexual blood-stage transcriptome of 21 *P. falciparum* lines, from four subclonal groups. Transcriptional heterogeneity among essentially isogenic parasites was observed.                                                                                                                                                                                                                       [@B114]
  *P. falciparum 3D7*                                                                      Peripheral blood samples from infected patients                                                                                                                                           Microarray         *In vivo* gene expression profiles of parasites isolated from clinical samples. Expression profiles clustered into three distinct groups corresponding to distinct physiological states: glycolytic growth, starvation response, or general (non-nutritional) stress response.                                                                                                                    [@B31]
  *P falciparum 3D7 and NF54*                                                              Sporozoites and gametocytes(3D7 stages II, III, and V; NF54, stage V)                                                                                                                     Quantitative PCR   Transcript profiles of *rif* and *var* genes. A single rif gene, PF13_0006, showed high transcript abundance in mature gametocyte stage V and in sporozoites.                                                                                                                                                                                                                                     [@B141]
  *P. falciparum* FcB1                                                                     Late schizont/merozoite stages and rings/trophozoites/early schizonts stages                                                                                                              ESTs               EST library of highly synchronized *P. falciparum* parasites to isolate genes selectively expressed during merozoite morphogenesis, using SSH\*. Identified genes selectively expressed during the last hours of the erythrocytic cycle. Subsequently identified 243 protein coding genes, including 121 hypotheticals, by sequencing 22,125 clones from the SSH library.                         [@B47], [@B48])
  *P. falciparum 3D7*                                                                      Asexual erythrocytic stage at 8 time points post-infection (5, 10, 15, 20, 25, 30, 35, and 40 h)                                                                                          RNA-seq            RNA-seq analysis of the transcriptome throughout intraerythrocytic development. Variation in overall transcriptional activity with stage-specific regulation (low at early stages, peaking at trophozoite stage).                                                                                                                                                                                 [@B8]
  *P. falciparum 3D7*                                                                      Asexual erythrocytic stage at seven time points post-infection                                                                                                                            RNA-seq            Illumina-based RNA seq throughout intraerythrocytic development. Identified 107 novel transcripts and 38 pseudogenes, with many demonstrating differential expression over time.                                                                                                                                                                                                                  [@B100]
  *P. falciparum 3D7*                                                                      Seven life cycle stages: two gametocyte stages (II and V), ookinete, and four asexual erythrocytic stages (ring, early trophozoite, late trophozoite, and schizont                        RNA-seq            Transcriptomic analysis of asexual and sexual stages. Identified many unknown splicing junctions and stage specific gene expression including occyst-specific genes.                                                                                                                                                                                                                              [@B81]
  *P. falciparum 3D7*                                                                      Parasites cultured *in vitro*, as well as two pools of field isolates from *Plasmodium*-infected pregnant women and children                                                              NSR-seq            Transcriptome of *in vitro* and *in vivo* blood stages. Identified a subset of genes upregulated in parasite-infected pregnant women; and a subset of genes that differentiated parasites infecting children from parasites infecting pregnant women.                                                                                                                                             [@B140]
  *P. falciparum 3D7*                                                                      Mixed asexual erythrocytic stages                                                                                                                                                         ESTs               7,683 *P. falciparum* 3D7 ESTs were generated from mixed asexual stages.                                                                                                                                                                                                                                                                                                                          [@B153]
  *P. falciparum 3D7*                                                                      Asexual erythrocytic stages                                                                                                                                                               SAGE               Transcriptional profile of erythrocytic stages in different studies.                                                                                                                                                                                                                                                                                                                              [@B103], [@B57], [@B56])
  *P. vivax clinical isolates*                                                             Peripheral blood samples from infected patients                                                                                                                                           Microarray         Complete transcriptional profile throughout the intraerythrocytic cycle of three clinical isolates from acute *P. vivax* patients. Identified distinct expression patterns genes predicted to encode proteins associated with virulence and host pathogen interactions.                                                                                                                           [@B19]
  *P. vivax Sal-1*                                                                         Human and mosquito stages, including sporozoites, gametes, zygotes and ookinetes, and *in vivo* asexual blood stages                                                                      Microarray         Characterization of the *P. vivax* transcriptome. Distinct stage-specific expression profiles. Identified DNA sequence motifs upstream of co-expressed genes that are conserved across different species.                                                                                                                                                                                         [@B144]
  *P. yoelii yoelii 17X*                                                                   Infected hepatocytes at 3 timepoints post-infection (24, 40 and 50 hr); midgut-oocyst sporozoites and salivary gland sporozoites; and mixed blood stages and blood-stage schizonts        Microarray         Profile of genome-wide liver stage gene expression was compared with other life cycle stages. Identified 1985 genes active during liver stage development including 1000 upregulated genes and 174 genes that were more abundant or unique in the liver stage.                                                                                                                                    [@B134]
  *P. falciparum*                                                                          cDNA from *P. falciparum* salivary gland sporozoites vs. sporozoites co-cultured with human primary hepatocytes for 1 h                                                                   Microarray         Transcriptome of salivary gland sporozoites was compared with that of sporozoites co-cultured with hepatocytes. 532 genes were up-regulated and 79 genes downregulated following co-culture, in comparison to non-exposed salivary gland sporozoites. Two proteins with temporal upregulation (PFD0425 \[SIAP1\] and Pf08_0005 \[SIAP2\]) implicated in both traversal and hepatocyte invasion.   [@B128]
  *P. yoelii yoelii 17XNL*                                                                 Midgut sporozoites and salivary gland sporozoites                                                                                                                                         Microarray         Comparative transcriptome study of *P. yoelii* oocyst sporozoites and salivary gland sporozoites. 124 genes were upregulated and 47 downregulated in salivary gland sporozoites. Similar transcription profiles of 11 *P.falciparum* orthologs confirmed by qPCR.                                                                                                                                 [@B87]
  *P. yoelii yoelii 17X*                                                                   cDNA library from *P. yoelii* liver stages laser-capture microdissected at 40 h post infection                                                                                            EST                623 non-redundant genes were identified, of which 25% were unique to the liver stage.                                                                                                                                                                                                                                                                                                             [@B118]
  *P. berghei HPE and HP*                                                                  Non-gametocyte producing clone (HPE) and gametocyte producing clone (HP); rings, young trophozoite, young schizont, young gametocyte, mature trophozoite, mature and mature gametocytes   Microarray         Comparative transcriptomes of non-gametocyte and p gametocyte producing clones of *P. berghei*. 215 and 355 genes were upregulated in the G1 and the S/M phases, respectively. 58% of the G1 proteins (125 genes) and 59.4% of the S/M proteins (199 genes) were also up-regulated in gametocytes.                                                                                                [@B61]
  *P. falciparum 3D7, P. vivax Sal-1, P. yoelii, P. berghei ANKA*                          Full-length cDNA libraries (all stages)                                                                                                                                                   ESTs               Comparative transcriptomes of full-length cDNA sequences of *P. falciparum* (12,484 cDNAs), *P. vivax* (9,633 cDNAs), *P. yoelii* (11262), and *P. berghei* (1518 cDNAs).                                                                                                                                                                                                                         [@B142]

\*SSH, suppression subtractive hybridization

.

In addition to this genomic data, the rapid development of high throughput technologies for profiling the transcriptome, proteome, metabolome, and interactome, including capillary liquid chromatography, tandem mass spectrometry (LC-MS/MS), Multidimensional Protein Identification Technology (MudPIT), microarray DNA chip, yeast two-hybrid (Y2H) screening and most recently RNA seq and NSR-seq ([@B145]) can be applied for the rational identification of potential vaccine candidate antigens.

In early studies, proteomes of four stages of the *P. falciparum* parasite life cycle (sporozoites, merozoites, trophozoites, and gametocytes) were revealed by MudPIT ([@B46]) as well as the proteome of the asexual blood stages (trophozoites and schizonts) and sexual stages (gametocytes and gamete) by LC-MS/MS analysis ([@B73]). This *P. falciparum* sporozoite proteome included a total of 1048 proteins of which almost half (49%) were unique to this stage. The proteomes of *P. berghei* oocysts and sporozoite were subsequently defined by MudPIT in 2005, resulting in the identification of 1836 proteins ([@B61]). Recently, nano-liquid chromatography (nanoLC) coupled high-resolution MS was applied to profile the proteome of highly purified salivary gland sporozoites from *P. falciparum* and *P. yoelii*, identifying a total of 1991 *P. falciparum* sporozoite proteins and 1876 *P. yoelii* sporozoite proteins ([@B78]).The liver stage proteome was defined in the rodent host *P. yoelii* by LC-MS/MS resulting in the detection of 712 proteins in the liver stage schizont proteome, with 174 of them more abundant and/or detected only in the liver stage ([@B134]).

A study of *P. falciparum* infected erythrocytes, fractionated through biotin-streptavidin interaction and analyzed by MudPIT, identified 164 proteins of the 423 proteins that were enriched the in biotin-labeled fractions and thus considered surface proteins. Among these were known secreted proteins, such as Exp-1 and Exp-2, and rhoptry proteins (RAP-1, -2, and -3, RhopH-2 and -3; [@B45]). Another LC-MS/MS study of early stages from *P. falciparum* clinical isolates detected 88 *P. falciparum* proteins in the peripheral circulation ([@B1]). More recent analyses on the proteome of asexual trophozoites, early gametocytes, and mature gametocytes from *in vitro* culture by high accuracy (LC MS/MS) have identified over new 1000 parasite proteins, not previously identified ([@B129]). Most recently, proteomic analysis by MudPIT of *P. falciparum* nuclei of ring, trophozoite and schizont stages has elucidated the nuclear proteome of *P. falciparum* during intra-erythrocytic development, consisting of over 800 proteins ([@B95]).

Elucidation of the gametocyte sex-specific proteomes of *P. falciparum* by LC-MS/MS resulted in the identification of 305 unique proteins in the male gametocyte proteome and 170 unique proteins in the female gametocyte proteome ([@B66]). The identification of sex-specific proteins has brought new insight in understanding the role of these proteins during the sexual differentiation and thus proving the basis for identifying targets for the interruption of transmission, either by drugs or vaccines.

Other comparative LC MS/MS proteomic studies of *P. falciparum* and *P. berghei* have identified novel proteins in the pre-erythrocytic stages of the *Plasmodium* life cycle: 127 proteins in the oocyst proteome, 450 proteins in oocyst-derived sporozoites and 477 proteins in salivary gland sporozoites, for a total of 728 *Plasmodium* proteins, of which 250 were exclusively detected in the oocyst/sporozoite stages when compared to the *P. falciparum* blood stage proteome ([@B74]).

More recently, the proteome of *P. vivax* asexual schizonts has been defined by analyzing fresh parasite isolates from patients exposed to *P. vivax* by tandem MS/MS ([@B113]).

Complementing the proteomic analyses, a number of transcriptomics studies have been undertaken, ranging from analysis of gene transcription using random clones selected from genomic DNA libraries to more recent global expression transcription profile using oligonucleotide microarray, RNA-seq or NSR-seq. Transcriptomic data are now available from multiple life-cycle stages or gene knock-out mutants of *P. falciparum* and *P. berghei* as well as multiple stages of *P. yoelii* (mosquito, erythrocytic and liver stages; **Table [3](#T3){ref-type="table"}**). Specifically, transcriptomic data available for *P. falciparum* include genome-scale transcriptomic analyses of nine different life cycle stages (3D7 strain) including salivary gland sporozoite, early and late ring stage, early and late trophozoite, early and late schizont, merozoite, and gametocyte stages ([@B76]); the intraerythrocytic trophozoite and schizont stages ([@B18]); the intraerythrocytic developmental cycle of *P. falciparum* HB2, Dd2, and 3D7 strains ([@B80]); as well as 21 other *P. falciparum* lines from four subclonal groups (3D7A/3D7B, 7G8, D10, HB3A/HB3B) during the asexual intraerythrocytic developmental cycle at seven time points post-infection (10, 20, 30, 34, 37, 40, or 43 h; [@B114]) plus analysis of parasites derived directly from blood samples from 43 infected patients ([@B31]). The transcriptome of high-purity stage I-V *P. falciparum* gametocytes is also available ([@B151]), as well as the transcript profiles of rif and var genes at different stage of gametocytogenesis ([@B141]).

In addition to genome-wide gene expression studies, RNA-seq analysis of the *P. falciparum* transcriptome is available for multiple time points during the intraerythrocytic developmental cycle ([@B8]; [@B100]; [@B81]); and two gametocyte stages ([@B81]). The transcriptional profile of two pools of field isolates from malaria-infected pregnant women and children has been also determined by NSR-seq ([@B140]).

For *P. vivax*, transcriptomic data include genome-scale transcriptomic analyses throughout the intraerythrocytic cycle of three distinct *P. vivax* isolates ([@B19]) as well as sporozoites co-cultured with hepatocytes ([@B128]); and sporozoites, gametes, zygotes, and ookinetes, and asexual blood stages obtained from infected patients ([@B144]).

*Plasmodium yoelii* gene expression data are available for oocyst sporozoites and salivary gland sporozoites ([@B87]); three time points during the liver stage (24, 40, and 50 h post-infection), two time points during the mosquito stage (midgut-oocyst sporozoites and salivary gland sporozoites; [@B134]), and two intraerythrocytic stages ([@B134]). *P. berghei* expression data are available for rings, young trophozoites, young schizonts, and mature schizonts ([@B61]).

Other transcriptomic datasets include EST data from cDNA libraries of *P. falciparum* (12,484 cDNA sequences), *P. vivax* (9,633 cDNAs), *P. yoelii* (11,262 cDNAs), and *P. berghei* (1,518 cDNAs) ([@B142]; [@B134]), as well as 7,683 *P. falciparum* 3D7 ESTs generated from mixed asexual stages and SAGE data ([@B103]; [@B57], [@B56]).

These genome-wide genomic, proteomic, and transcriptomics analyses (**Tables [1](#T1){ref-type="table"}**--**[3](#T3){ref-type="table"}**) have revealed potential antigens expressed in the sporozoite and intrahepatic stages and novel proteins on the surface of malaria-infected erythrocytes that may play a role in pathogenesis and immunity, and that may represent potential new vaccine candidates.

Several novel parasite surface antigens have been discovered ([@B46], [@B45]; [@B73]; [@B75]; [@B119]) but, so far, this wealth of data has yielded few new vaccine targets (**Table [4](#T4){ref-type="table"}**; [@B41]). In our opinion, translation of this wealth of information from the large-scale genomic, proteomic, and transcriptomic datasets into practical application, such as the identification of promising new target antigens for vaccine development, requires integrating this knowledge with functional outputs such as biologically relevant immune responses. Thus, in our laboratory, we are pursuing immunomics-based approaches which integrate the disciplines of genomics and immunology using biological samples from humans or animals with immunity to the disease of interest to identify the subset of pathogen-derived proteins or their epitopes that are recognized by the host immune system ([@B69]; [@B32]). No vaccines derived from immunomics have yet reached the stage of clinical testing but a number of promising candidate antigens have been identified by us in the malaria model using antibody based ([@B38]; [@B29]; [@B137]) or T-cell based ([@B40]; [@B32]). We are using peripheral blood mononuclear cells (T cells) and plasma/sera (antibodies) from individuals experimentally immunized with RAS or CPS or naturally exposed to malaria for proteome-wide immune screening assays using clinically relevant selection criteria to identify the key antigens and their epitopes recognized by recall *Plasmodium*-specific immune responses in protective human models. Data generated to date establish proof-of-concept for both T cell and antibody based approaches to identify from genomic datasets the subset of antigens and epitopes which represent promising candidates for next generation malaria vaccine development ([@B32]; [@B83]; [@B33]; **Table [4](#T4){ref-type="table"}**).

###### 

*Plasmodium* antigens identified from genome-based datasets.

  Antigen                                                    Model                                                                                             Main finding                                                                                                                                                                                                                                                                                                           Reference
  ---------------------------------------------------------- ------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------
  Ag2/CelTOS                                                 *P. falciparum* RAS T cell screening;*P. yoelii* and *P. berghei* murine immunization/challenge   One of four highly reactive *P. falciparum* proteins identified by T cell based screening of 27 putative proteins with RAS immunized volunteers; conferred cross-species protection against *P. yoelii* and *P. berghei* sporozoite challenge.                                                                         Doolan (in preparation), [@B40]; [@B14]
  Thirty-four pre-erythrocytic antigens                      *P. yoelii* murine immunization/challenge                                                         Only three antigens (P33p\[*Py*52\] \[PY01340\], Ag2 \[*Py*CelTOS\], and Ag5\[PY00419\] elicited CD8^+^ T cell responses but none conferred protection.                                                                                                                                                                [@B88]
  PY03011, PY03424, and PY03661: pre-erythrocytic antigens   *P. yoelii* murine immunization/challenge                                                         The combination of the three antigens (but not individual antigens) conferred sterile protection against *P. yoelii* sporozoite challenge in a high proportion of mice.                                                                                                                                                [@B77]
  PyTmp21(PY06414): pre-erythrocytic antigen                 *P. yoelii* murine immunization/challenge                                                         *Py*Tmp21 elicited functional immunity that significantly reduced liver stage parasite burden following *P. yoelii* sporozoite challenge.                                                                                                                                                                              [@B26]
  PbS20 and PbTRAP pre-erythrocytic antigens                 *P. berghei* murine immunization/challenge                                                        Systematically evaluated H(2b)-restricted peptides predicted from genome-wide analysis, and identified two epitopes as targets of CD8^+^ T cells induced by whole parasite vaccines; CD8^+^ T cells specific for the *Pb*TRAP epitope but not the PbS20 epitope inhibited liver stage parasite development *in vivo*   [@B59]
  PyTAM: blood-stage antigen                                 *P. yoelii* murine immunization/challenge                                                         *Py*TAM elicited functional immunity that conferred significant protection against mortality from lethal *P. yoelii* challenge infection.                                                                                                                                                                              [@B27]
  Py01157: sexual and sexual stage antigen                   *P. yoelii* murine immunization/challenge                                                         *Py*01157: conferred partial protection against challenge with non-lethal *P. yoelii* 17XNL, but not against challenge with lethal *P. yoelii* 17XL.                                                                                                                                                                   [@B154]

In the initial proof-of-concept study ([@B38]) for the application of protein microarray technology for antigen discovery, a protein microarray with 250 pre-erythrocytic *P. falciparum* proteins were probed with sera from individuals with sterile immunity or no immunity against experimental challenge following vaccination with radiation-attenuated *P. falciparum* sporozoites, partial immunity acquired by natural exposure, or no previous exposure to *P. falciparum*, to identify 72 highly reactive P. falciparum antigens. Subsequently, a larger protein microarray containing 2,320 *P. falciparum* proteins fragments (corresponding to 1200 *P. falciparum* proteins, ∼25% of the proteome) was screened with plasma from clinically divergent groups of individuals immunized with *P. falciparum* irradiated sporozoites and identified a signature of 16 antigens strongly associated with RAS-induced sterile protective immunity; responses to any individual antigen were not associated with protection ([@B137]). Using this same protein microarray, plasma from children and young adults naturally exposed to malaria in an endemic area of Mali were screened and 46 novel proteins significantly associated with a reduction of re-infection in the subsequent malaria season were identified ([@B29]). One *P. falciparum* antigen identified by T cell based screening of RAS-immunized volunteers ([@B40]), known as Ag2 or CelTOS ([@B65]), has been shown to be a target of cross-species protection in the murine model ([@B14]). Another *P. yoelii* antigen, PyTmp1, could induce immune responses that reduced liver stage parasite burden *in vivo* ([@B26]), and three other *P. yoelii* antigens in combination (but not individually) could induce sterile immunity in a high proportion of immunized mice ([@B77]). Two *P. yoelii* blood stage antigens, PyTAM and Py01157, have been also associated with partial protection in the murine model ([@B154]; [@B27]; **Table [4](#T4){ref-type="table"}**). These data support the potential of genome-based antigen discovery. Assessment of the protective capacity of promising new antigens discovered by genome-based screening is currently a bottleneck in the preclinical development pipeline. Development and refinement of a high throughput screening system would overcome this obstacle and allow the development of a rationally designed genome-based vaccine against malaria.

CONCLUSION
==========

We advocate a modern genome-based approach to rational vaccine design which takes advantage of the wealth of genomic, proteomic, and transcriptomic datasets, using biological samples from humans or animals with immunity to the disease of interest and functionally relevant screening criteria to identify the key antigens and their epitopes targeted by protective immune responses. With this focus, we can improve on nature. In the case of malaria, validated human challenge models provide a valuable resource for genome-based antigen discovery. Moreover, this information can be integrated with other omic-based and cutting-edge immunological based approaches. For example, systems immunology could be applied to identify immune signatures that distinguish a protective immune response from a non-protective one. The many technological and intellectual advances in the omics era offer great potential for the development of rationally designed vaccines against malaria as well as other pathogens that have thus far proved elusive.
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